High-Sensitivity C-Reactive Protein and Cardiovascular Disease Across Countries and Ethnicities by Fonseca, Francisco Antonio Helfenstein & Izar, Maria Cristina de Oliveira
High-Sensitivity C-Reactive Protein and Cardiovascular
Disease Across Countries and Ethnicities
Francisco Antonio Helfenstein Fonseca,* Maria Cristina de Oliveira Izar
Universidade Federal de Sa˜o Paulo, Departamento de Medicina, Divisa˜o de Cardiologia, Sa˜o Paulo/SP, Brazil.
Despite substantial differences in ethnicities, habits, cultures, the prevalence of traditional cardiovascular risk
factors and affordable therapies, atherosclerosis remains the major cause of death in developing and developed
countries.
However, irrespective of these differences, inflammation is currently recognized as the common pathway for
the major complications of atherosclerosis, stroke, and ischemic heart disease. A PubMed search was conducted
for ‘‘high-sensitivity C-reactive protein’’ (hs-CRP) in combination with the terms race, ethnicity, gender,
prevalence, geographic, epidemiology, cardiovascular, obesity, diabetes, hypertension, cholesterol, smoking,
ischemic heart disease, stroke, and mortality. This review includes the articles that pertained to the topic and
additional articles identified from the reference lists of relevant publications.
This review describes the marked differences in cardiovascular mortality across countries and ethnicities, which
may be attributed to inequalities in the prevalence of the classic risk factors and the stage of cardiovascular
epidemiological transition. However, hs-CRP appears to contribute to the prognostic information regarding
cardiovascular risk and mortality even after multiple adjustments. Considering the perception of cardiovascular
disease as an inflammatory disease, the more widespread use of hs-CRP appears to represent a valid tool
to identify people at risk, independent of their ancestry or geographic region. In conclusion, this review
reports that the complications associated with vulnerable atherosclerotic plaques are triggered by the major
mechanisms of dyslipidemia and inflammation; whereas both mechanisms are influenced by classic risk factors,
hs-CRP contributes additional information regarding cardiovascular events and mortality.
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’ INTRODUCTION
Currently, the link between inflammation and cardiovas-
cular disease (CVD) appears to be firmly established (1-3).
Among the several biomarkers that have been proposed for
cardiovascular risk stratification, high-sensitivity C-reactive
protein (hs-CRP) appears to contribute to the identification of
people at risk of developing CVD (4-8); however, the
evaluation of hs-CRP has not yet been widely recommended
in guidelines (9-11). Although some differences in the
absolute event rates in patients with similar hs-CRP levels
have been reported between genders and ethnicities (12,13),
the reliability of hs-CRP determination appears to be valid
for all patients, even after multiple adjustments (14). In light
of the increased cardiovascular mortality in developing
countries, a critical analysis of the available research on hs-
CRP with respect to different countries and ethnic groups
appears warranted.
CRP Levels, Ethnicities, and Cardiovascular Events
South and East Asians
In the Japan Collaborative Cohort study (15), subjects from
45 communities in Japan (13,282 men and 24,487 women)
were followed for up to 13 years. After multiple adjustments,
the hs-CRP levels in the highest quartile (40.85 mg/L)
versus the lowest quartile (o0.19 mg/L) were positively
associated with CVD in men. In women, the hs-CRP levels in
the highest quartile (40.93 mg/L) versus the lowest quartile
(o0.19 mg/L) were also positively associated with CVD
(Table 1).
In the Hisayama study (16), a Japanese population-based,
prospective cohort study, 2,589 participants were followed for
14 years. The annual incidence rates of coronary heart disease
(CHD) progressively increased with increasing hs-CRP levels.
The risk of CHD in the highest quartile group was 2.98-fold
higher than the risk in the lowest quartile (Table 1).
Among the Chinese participants (n=1,847) enrolled in the
Hong Kong Cardiovascular Risk Factors Prevalence Study 2
(CRISPS 2) (17) and followed for a median of 9.4 years, theDOI: 10.6061/clinics/2016(04)11
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subjects with incident CVD had higher median (interquartile
range [IQR]) hs-CRP levels (1.28 [0.63–2.42]) than those
without CVD (0.68 [0.33–1.47]); po0.001 (Table 1).
A meta-analysis that included South and East Asian
populations showed differences in the hs-CRP levels between
these populations. Although the median hs-CRP level was 2.63
mg/L among the South Asian population, a lower median level
(0.97 mg/L) was found among the East Asian population (18).
In the Indian Atherosclerosis Research study (19), hs-CRP
levels were quantified in 774 subjects with coronary artery
disease (CAD) and 1,544 asymptomatic individuals. During
the 4-year follow-up period, the patients in the highest
quartile of hs-CRP level (43.58 mg/L) had a 4-fold higher
risk for coronary events than patients in the first quartile
(o0.7 mg/L) (Table 1).
Taken together, these studies suggest that the hs-CRP
levels in these populations may vary according to the geo-
graphic region; however, despite these differences, the hs-
CRP levels remained related to cardiovascular risk.
Africans and African-Americans
An interesting study compared the hs-CRP levels between
African-Americans (n=1,510) from the US and Africans from
Nigeria (n=1,254) (20). In this cross-sectional analysis, the hs-
CRP levels were higher among the African-Americans than
among the Nigerians, suggesting differences among related
ethnic groups living in countries at different stages of
development.
The Profiles of Obese Women with the Insulin Resistance
Syndrome (POWIRS) study included African (n=102) and
Caucasian (n=115) women from South Africa (21). Higher
mean hs-CRP levels were observed among the African women
(4.91 mg/L) than among the Caucasian women (2.99 mg/L),
suggesting differences in the hs-CRP levels between two
different ethnic groups living in the same country.
Differences in hs-CRP levels were also observed in the Study
ofWomen’s Health Across the Nation (SWAN) study (22), which
included 3,154 women in the United States without prior CVD.
African-American women had the highest median hs-CRP levels
(3.2 mg/L), followed by Hispanic (2.3 mg/L), white (1.5 mg/L),
Chinese (0.7 mg/L), and Japanese (0.5 mg/L) women.
Similar results were found in the Multi-Ethnic Study of
Atherosclerosis (MESA) study in the US; higher mean hs-CRP
levels were detected among African-Americans (4.34 mg/L),
followed by Hispanics (4.06 mg/L), Caucasians, (3.32 mg/L)
and Chinese individuals (1.73 mg/L). According to the
findings of the MESA study, hs-CRP levels were predictive
of CVD only in Caucasians (23).
In a meta-analysis involving 18,585 subjects of African
ancestry (African-Americans, African-Caribbeans, and Afri-
cans from Nigeria and Kenya), hs-CRP levels were higher in
the African ancestry group (geometric mean, 2.60 mg/L)
than among Hispanics (2.51 mg/L, n=5,049), South Asians
(2.34 mg/L, n=1,053), Caucasians (2.03 mg/L, n=104,949),
and East Asians (1.01 mg/L, n=39,521) (18).
In the Reasons for Geographic and Racial Differences in
Stroke (REGARDS) study (24), African-Americans (n=7,853)
had a median (IQR) hs-CRP of 2.8 (5.1) mg/L, which was
higher than the level observed in the Caucasian population
(n=11,238) with a median (IQR) hs-CRP of 1.8 (3.2) mg/L.
Table 1 - High-sensitivity C-reactive protein levels and cardiovascular disease events according to countries and ethnic groups.
Author Country Clinical trial hs-CRP cut-off
Iso et al. (15) Hs-CRP levels were measured using an ultra-
sensitive latex-enhanced immunoassay with an automatic
analyzer (BN ProSpec Nephelometer; Dade Behring, Tokyo,
Japan)
Japan Japan
Collaborative
Cohort Study
Lowest (o0.19 mg/L) vs highest (40.85 mg/L) quartile
Correlated with cardiovascular mortality in men Lowest
(o0.19 mg/L) vs highest (40.93 mg/L) quartile
Correlated with cardiovascular mortality in women
Arima et al. (16) Serum hs-CRP levels were analyzed using a
modification of the Behring latex-enhanced CRP assay on a BN-
100 nephelometer (Dade Behring) with a 2% interassay
coefficient of variation
Japan Hisayama
study
Lowest (o0.21 mg/L) vs highest (41.02 mg/L) quartile
Correlated with coronary heart disease
Chow et al. (17) CRP was measured using a high-sensitivity,
particle-enhanced immunoturbidimetric assay
China CRISPS 2
study
Comparison, 41 vs o1 mg/L Correlated with
cardiovascular disease
Rao et al. (19) Plasma hs-CRP levels were measured using the
Roche Tina-Quant CRP (Latex) kit (Roche Diagnostics, Basel,
Switzerland)
India Lowest (o0.7 mg/L) vs highest (43.58 mg/L) quartile
Correlated with coronary events
Veeranna et al. (23) CRP was measured using the BN II
Nephelometer (N High-Sensitivity CRP; Dade Behring)
United
States
MESA study hs-CRP levels correlated with cardiovascular disease only
in Caucasians
Tabak et al. (25) CRP was measured using a high-sensitivity
immunonephelometric assay with a BN ProSpec Nephelometer
(Dade Behring, Eschborn, Germany)
United
Kingdom
hs-CRP levels correlated with diabetes/fatal
cardiovascular disease
Cox et al. (26) United
States
hs-CRP levels correlated with mortality in European
Americans with type 2 diabetes
Ridker et al. (4) CRP was measured using an enzyme-linked
immunosorbent assay (ELISA) based on purified protein and
polyclonal anti–C-reactive protein antibodies (Calbiochem,
San Diego, CA, USA)
United
States
Lowest (p0.55 mg/L) vs highest (X2.11 mg/L) quartile
Correlated with myocardial infarction and stroke in male
physicians
Ridker et al. (27) United
States
Lowest (median, 1.2 mg/L) vs highest (median, 4.4 mg/L)
quartile Correlated with cardiovascular events in women
Albert et al. (28) Global hs-CRP levels correlated with cardiovascular events in
male and female participants in the JUPITER trial
(independent of ethnic group)
All studies were observational (except the JUPITER trial).
hs-CRP: high-sensitivity C-reactive protein; CRISPS 2: Cardiovascular Risk Factors Prevalence Study 2; MESA, Multi-Ethnic Study of Atherosclerosis.
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Caucasians
The Whitehall II study (25), a long-term prospective cohort
of 7,350 British civil servants, examined the relationship
between baseline hs-CRP levels and outcomes during a
median follow-up of 414 years. The baseline CRP levels
(median [IQR]) were higher among participants who had
fatal CVD events (1.49 [2.47] vs 0.84 [1.30] mg/L; po0.0001)
than among controls.
In the MESA study (23), Caucasian participants (n=2,362)
were followed for a mean of 4.6 years. A positive association
was observed between the hs-CRP levels and cardiovascular
events (hazard ratio [HR], 1.23; 95% confidence interval [CI],
1.04–1.47; po0.01).
In the Diabetes Heart Study (26), baseline hs-CRP levels
were measured in 846 subjects with type 2 diabetes who
were followed-up for a mean (standard deviation [SD]) of
7.3 (2.1) years. By the end of the study follow-up, the patients
with baseline hs-CRP levels of 3–10 mg/L were 2 times more
likely to be deceased and the patients with hs-CRP levels
410 mg/L were 5 times more likely to be deceased.
In the Physicians’ Health Study (4) that evaluated
apparently healthy and predominantly white male physicians
in the US, hs-CRP was related to adverse cardiovascular
outcomes. The subjects in the highest quartile of hs-CRP
(X2.11 mg/L) had a 3 times higher incidence of myocardial
infarction and 2 times higher incidence of ischemic stroke
than the subjects in the lowest quartile (p0.55 mg/L). In the
Women’s Health study (5) that involved predominantly
white women, the participants in the highest hs-CRP quartile
(median, 8.5 mg/L) had 4.4 times more cardiovascular events
than those in the lowest hs-CRP quartile (median, 0.6 mg/L;
po0.001).
Hispanics
The Justification for the Use of Statins in Prevention: an
Intervention Trial Evaluating Rosuvastatin (JUPITER) trial
(27,28) was a primary prevention study that included 12,683
white and 5,117 non-white subjects with low-density lipopro-
tein (LDL) cholesterol levels o130 mg/dL (3.4 mmol/L) and
hs-CRP levels X2 mg/L. The non-white population in the
study included 2,224 blacks, 2,261 Hispanics, and 632 Asians
or members of other ethnic groups. The non-white population
had higher median (IQR) baseline hs-CRP levels than the
white population (5.1 [3.2–8.8] vs 4.0 [2.7–6.5] mg/L).
Additionally, the baseline median IQR hs-CRP levels were
higher among blacks than in the other ethnic groups (blacks,
6.2 [3.7–11.1] mg/L; Hispanics, 4.4 [2.9–7.1] mg/L; and whites,
4.0 [2.7–6.5] mg/L). Whereas all 3 ethnic groups had the same
age and body mass index (BMI) profiles, differences were
demonstrated in their hs-CRP levels. The event rates for the
whites and non-whites (Hispanics and blacks) per 100 person-
years of follow-up were 1.44 and 1.11 in the placebo groups,
respectively. After multiple adjustments, these results were
considered similar for both of the ethnic groups, suggesting
that the higher hs-CRP levels among the blacks and Hispanics
may not be related to the same increase in the absolute risk
observed in the Caucasians.
Cardiovascular Risk Factors Related to Hs-CRP by
Countries and Ethnicities Obesity
Obesity is related to hypertension, diabetes, CVD and to
a chronic inflammatory state. In the Canadian Health
Measures Survey (29), hs-CRP levels were evaluated in 1,805
subjects. The mean (standard error) hs-CRP levels were 0.65
(1.15), 1.26 (1.16), and 2.28 (1.16) mg/L in normal-weight,
overweight, and obese subjects, respectively.
A systematic review and meta-analysis (30) that included
51 cross-sectional studies (76,444 American/European and
59,040 Asian subjects) confirmed the relationship between
hs-CRP and BMI as well as the relationship with waist
circumference and waist-to-hip ratio. This correlation was
higher among women (0.53 [95% CI, 0.45–0.60]) than men
(0.24 [95% CI, 0.19–0.29]) in the North American/European
populations. The correlation observed in these ethnic groups
was consistently higher than that observed in the Asian
population.
Marked differences in the prevalence of obesity were
observed across countries from Europe, Asia, Africa, and the
US. Furthermore, according to the World Health Organiza-
tion (WHO) (31), the lowest prevalence of obesity was
reported in some countries in Eastern and Southern Asia and
countries from Eastern or Central Africa. Conversely, a high
prevalence of obesity has been reported in few countries
in Africa, whereas it was widely reported in European
countries and the US.
Diabetes
In a cross-sectional study involving 1,730 Chinese subjects,
a glucose tolerance test was performed and the participants
were classified as having normal glucose tolerance (NGT,
n=1,258), impaired fasting glucose (IFG, n=126), or im-
paired glucose tolerance (IGT, n=346) (32). After multiple
adjustments, the odds ratios (ORs) across the quartiles of hs-
CRP remained associated with IFG and IGT. The geometric
mean ([SD]) levels for hs-CRP were 1.18 (2.48), 2.47 (3.52),
and 2.42 (3.17) mg/L for NGT, IFG, and IGT, respectively.
In a cross-sectional study that included 822 men and 1,097
women in Japan, an association was observed between fasting
glucose levels and hs-CRP, but only for women. The hs-CRP
levels progressively increased with higher fasting glucose
levels between 90 mg/dL (5.0 mmol/L) and 125 mg/dL (6.9
mmol/L), or known diabetes (33). An association between
increasing hs-CRP levels and worsening insulin resistance was
also reported in a South Asia (India) study (34).
In the US, the MESA study (n=6,067 subjects) (23) assessed
the relationship between baseline hs-CRP and the incidence of
diabetes during a mean follow-up of 4.6 years in 4 ethnic
groups: Caucasians (38.9%), African-Americans (26.4%), His-
panics (22.3%), and Chinese-Americans (12.3%). A correlation
was observed between hs-CRP and the incidence of diabetes
(highest quartile vs first quartile; HR, 1.7; 95% CI, 1.3–2.4), and
the association was similar across all the ethnic groups.
In the British population of the Whitehall II study, baseline
hs-CRP levels were predictive of diabetes. After a mean
follow-up of414 years, the mean (SD) hs-CRP levels among
subjects who developed diabetes were 1.44 (2.39) and 0.78
(1.21) mg/L in subjects who developed diabetes and those
who remained free of diabetes, respectively (25).
High glucose levels have been reported in few countries in
Asia (India and Pakistan) and Africa (Libya, South Africa,
Nigeria, and Ghana), but were common in Eastern European
countries, North America, Central America, and South America.
The lowest prevalence of hyperglycemia has been reported in
countries in Eastern Asia, Eastern and Central Africa, parts of
Europe (Western, Northern, and Southern European countries),
and in some countries in Central and South America (31).
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Hypertension
Increased hs-CRP levels are predictive of incident hyper-
tension (35-39). A cross-sectional study in South Africa
evaluated 836 black subjects and tested the relationship
between hs-CRP levels and central blood pressure. Hs-CRP
levels were correlated with central blood pressure; however,
the associations did not persist after adjustments were made
for age, mean arterial blood pressure, and BMI (40). These
findings contrast with the results of studies in other ethnic
groups (41,42). The relatively high incidence of chronic
infections among the black African population may have
contributed to the high hs-CRP levels (42). Conversely,
another study involving obese white and black women in
South Africa showed high mean (IQR) hs-CRP levels
in patients with hypertension (3.50 [2.05–4.95] and 5.50
[3.04–7.95] mg/L, respectively), and both risk factors were
related to arterial compliance (43).
The lowest prevalence of hypertension has been reported
in East and South Asian countries, some regions of Europe
(Western, Southern, and Northern European countries), and
some countries in North and South America. The highest
prevalence of elevated blood pressure has been reported in
countries in Africa (all regions) and Eastern Europe and in
some Central and South American countries (31).
Smoking
In the Ludwigshafen Risk and Cardiovascular Health
(LURIC) study (n=3,316), baseline hs-CRP levels were
significantly higher in active smokers than in individuals
who had never smoked (4.9 vs 2.7 ng/mL) (44). A cross-
sectional survey conducted in 1,172 healthy men in the US
revealed that CRP levels increased in a stepwise manner for
patients who had never smoked, those who were former
smokers, and those currently smoking, with geometric mean
values of 1.0±2.5, 1.3±2.5, and 2.0±2.7 mg/L, respectively
(po0.001). Additionally, a positive association was observed
between CRP levels and the number of cigarettes smoked per
day (po0.01) among current smokers (45). Similar results
were reported among women in the US (n=340) in a nested
case-control study. Baseline hs-CRP levels were significantly
higher in women who were current smokers than in non-
smoking women (median [IQR], 0.38 [0.18–0.83] vs 0.3 [0.13–
0.57] mg/L, po0.032), even after multivariate analysis (p=
0.034). Significant increases were observed in hs-CRP levels
across women who had never smoked, former smokers, and
current smokers (p=0.041) (46).
In a hypertensive population from Japan, after multiple
adjustments CVD events were significantly higher among
current smokers than among former smokers. Moreover, the
CVD risk was higher in currently smoking women (HR, 6.1;
95% CI, 2.8–13.4; po0.001) than in men (HR, 1.4; 95% CI, 0.7–
2.8; p=0.41). The risk of CVD among current smokers was
significantly higher in the highest quartile of hs-CRP levels
than in the lower hs-CRP quartiles (47).
The lowest prevalence of smoking has been reported in Africa
(all regions), some countries in Northern Europe, and North and
Central America. The highest prevalence of smoking has been
reported in some countries of Eastern and Southern Asia,
Eastern,Western, and Southern Europe, and North America (31).
Hypercholesterolemia
Despite the weak association between cholesterol levels
and hs-CRP (48,49), hs-CRP determination is particularly
important for risk stratification in the presence of relatively
low cholesterol levels (6,27). Clearly, the association between
cholesterol levels and coronary mortality was established
based on observational studies (50,51). Additionally, however,
several meta-analyses (52-55) have demonstrated the benefits
of lowering LDL cholesterol to decrease total and cardiovas-
cular mortality rates, as well as several other cardiovascular
events. Thus, data from the WHO on hypercholesterolemia
around the world are also provided based on the impact of
this risk factor on cardiovascular mortality rates beyond that
of other risk factors that may affect hs-CRP levels. Cholesterol
levels 4200 mg/dL (5.2 mmol/L) are common in several
countries in all the European regions (Eastern, Western,
Northern, and Southern Europe) and are also highly prevalent
in the countries of North America. Conversely, a lower
prevalence of hypercholesterolemia has been observed in
Eastern and Southern Asia, all African regions, and in the
majority of countries of Central and South America (with a
few exceptions) (31).
Mortality Rates Due to Ischemic Heart Disease and
Stroke by Geographic Region
Marked differences in mortality rates due to ischemic heart
disease have been reported among Asian countries with
higher rates observed in Southern Asia (31).
Higher ischemic heart disease mortality rates have been
observed in Eastern Europe. High mortality rates for this
disease are also common in Africa, particularly in countries
in the northern region. Conversely, lower mortality rates due
to ischemic heart disease have been reported in countries in
Western, Northern, and Southern Europe. These rates were
not homogeneous in the Americas (Figure 1).
The highest mortality rates due to stroke have been
observed among African countries (mainly in the eastern,
central, and southern regions) and in Eastern Europe. High
rates for stroke mortality have also been observed in some
countries in Central and South America. In contrast, the
lowest rates for stroke mortality have been observed among
countries in the Western, Northern, and Southern European
regions (except Portugal) (Figure 2).
Significance of Hs-CRP for Risk Stratification
Increased global mortality is associated with atherosclero-
sis, considered an inflammatory disease (1-3,56), which
appears to be independent of race, culture, or the country’s
development stage. According to the WHO, the highest
ischemic heart disease mortality rates have been observed in
Southern Asia, Eastern Europe, and Africa. The prevalence of
cardiovascular risk factors across continents is heteroge-
neous; however, some regions with the highest hs-CRP levels
also have the highest prevalence of hypertension, diabetes,
and obesity. This association holds in Eastern Europe, a
region that also shares a high prevalence of hypercholester-
olemia. The high mortality rates in Africa due to ischemic
heart disease appear to be related to the high prevalence
of hypertension, hyperglycemia, and hypercholesterolemia.
In Southern Asia, the high mortality rates due to ischemic
heart disease appear to be related to the high prevalence of
diabetes and hypercholesterolemia.
With regard to mortality rates due to stroke, the highest
rates have been observed in Southern Asia, Africa, Eastern
Europe, and a few countries in Central America, which are
all regions with a high prevalence of hypertension.
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Interestingly, a recent analysis of the impact of low socio-
economic position (SEP) across the life span revealed that
this condition is related to high hs-CRP levels in adulthood
and appears to be at least in part independent of other
metabolic or traditional risk factors (57,58).
Levels of hs-CRP appear to correlate with cardiovascular
mortality rates, despite the marked differences in ethnicities
and the stage of disease control.
Based on their hs-CRP levels, at-risk individuals have
been identified in primary (59,60) and secondary (48,61)
Figure 1 - Estimated age-standardized death rates (per 100,000) due to ischemic heart disease in individuals of both sexes among Asian,
American, African, and European populations according to the World Health Organization (31). Values for countries with the lowest
and highest rates are shown per region.
Figure 2 - Estimated age-standardized death rates (per 100,000) due to cerebrovascular disease in individuals of both sexes among
Asian, American, African, and European populations according to the World Health Organization (31). Values for countries with the
lowest and highest rates are shown per region.
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cardiovascular prevention trials. A large ongoing trial, the
Canakinumab Anti-inflammatory Thrombosis Outcomes
Study (CANTOS) (62), includes individuals with persistently
high hs-CRP levels after myocardial infarction; it will
evaluate whether the use of anti-inflammatory therapy
reduces cardiovascular events.
Variability of Hs-CRP Concentrations by Populations
In the large JUPITER trial, hs-CRP concentrations were
determined in populations from Europe, Asia, Africa and the
Americas at screening, before randomization, and after years
1, 2, 3, and 4 of the study. The median hs-CRP concentrations
in the untreated population showed little change over these
years, declining from 3.8 mg/L at randomization to 3.4 mg/L
at 4 years. Thus, these results demonstrated a strong
persistence of hs-CRP concentrations, even in a selected
population of subjects with high baseline values. In the same
study (63), these findings regarding repeated hs-CRP
measurements were comparable to those observed for blood
pressure and lipid variables.
Recently, the evaluation of six-year changes in hs-CRP
concentrations was examined in the large Atherosclerosis
Risk in Communities (ARIC) study (64). Compared with
subjects with sustained low/moderate hs-CRP, those with
increased or sustained high hs-CRP had increased risks of
diabetes, coronary heart disease, ischemic stroke, heart
failure and mortality.
The intra-individual variability of C-reactive protein was
also tested in the Multi-Ethnic Study of Atherosclerosis
(MESA) (65). Even after multivariable adjustment, the intra-
class correlation coefficient (ICC) of hs-CRP was 0.62 (95% CI,
0.55-0.68), a value that was higher than the ICC observed for
total cholesterol and non-HDL-cholesterol. However, due to its
variability, the repeated measurement of hs-CRP appears more
appropriate than the use of a single sample value.
An interesting study conducted in a Chinese population
with type 2 diabetes revealed that hs-CRP concentrations
correlated with arterial stiffness as a continuous variable, in
multivariate models, even among individuals with low-grade
inflammation (66). The prevalence of some classic risk factors,
such as hypercholesterolemia and obesity, is lower in Japanese
and Chinese populations, which may partially explain their
lower levels of hs-CRP than those of other Asian populations.
However, even in these populations with lower cardiovascular
mortality rates, hs-CRP appears to be a continuous’’ variable
related to cardiovascular risk.
Finally, another interesting consideration is the stability of
CRP in stored samples. A recent study that examined hs-CRP
levels over 11 years of storage at -80oC found a coefficient of
correlation of 0.98, suggesting that under appropriate storage
conditions, the measurement of hs-CRP is not affected over
time (67).
Marked differences in the cardiovascular mortality rates
across countries and ethnicities may be attributed to inequal-
ities in the prevalence of classic risk factors and the stage of
the country’s development. However, according to a robust
meta-analysis, hs-CRP levels appear to provide additional
prognostic information on cardiovascular risk and mortality,
even after multiple adjustments (14). In fact, taking into
account the perception of CVD as an inflammatory disease, the
more widespread use of hs-CRP may represent an important
tool to identify people at risk, independent of their ancestry
or geographic region. The large ongoing CANTOS trial (62)
involves subjects from different geographic regions and could
answer important questions regarding the impact of anti-
inflammatory therapy on the development of major adverse
cardiovascular events (MACE). This study should also address
whether a need exists for the establishment of different hs-CRP
cut-off levels and the applicability of this biomarker for
different ethnicities. Figure 3 summarizes the significance of
the classic risk factors that influence the two major pathways
related to cardiovascular disease, lipids and inflammation.
In conclusion, this review reports that complications
involving the vulnerable atherosclerotic plaque are triggered
by two major mechanisms, dyslipidemia and inflammation;
although both are influenced by classic risk factors, each
mechanism provides additional information regarding cardio-
vascular events and mortality.
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Figure 3 - Increased cholesterol concentrations with oxidized
lipoproteins and inflammatory stimuli through the release of
cytokines with subsequent increase in C-reactive protein. Both
pathways are related to classic risk factors and contribute to the
development of and complications associated with vulnerable
atherosclerotic plaques. Thus, lipid and high-sensitivity C-reactive
protein determinants provide additional information regarding
cardiovascular risk. Strategies to control both mechanisms appear
germane to decreasing the global cardiovascular disease burden,
independent of ethnicity or geographic region.
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